Literature DB >> 33920701

Risk Factors for Mortality in Adult COVID-19 Patients Who Develop Bloodstream Infections Mostly Caused by Antimicrobial-Resistant Organisms: Analysis at a Large Teaching Hospital in Italy.

Brunella Posteraro1,2, Giulia De Angelis1,3, Giulia Menchinelli1,3, Tiziana D'Inzeo1,3, Barbara Fiori3, Flavio De Maio3, Venere Cortazzo1, Maurizio Sanguinetti1,3, Teresa Spanu1,3.   

Abstract

The aim of this study was to characterize COVID-19 (SARS-CoV-2-infected) patients who develop bloodstream infection (BSI) and to assess risk factors associated with in-hospital mortality. We conducted a retrospective observational study of adult patients admitted for ≥48 h to a large Central Italy hospital for COVID-19 (1 March to 31 May 2020) who had or had not survived at discharge. We included only patients having blood cultures drawn or other inclusion criteria satisfied. Kaplan-Meier survival or Cox regression analyses were performed of 293 COVID-19 patients studied, 46 patients (15.7%) had a hospital-acquired clinically relevant BSI secondary to SARS-CoV-2 infection, accounting for 58 episodes (49 monomicrobial and 9 polymicrobial) in total. Twelve episodes (20.7%) occurred at day 3 of hospital admission. Sixty-nine species were isolated, including Staphylococcus aureus (32.8%), Enterobacterales (20.7%), Enterococcus faecalis (17.2%), Candida (13.8%) and Pseudomonas aeruginosa (10.3%). Of 69 isolates, 27 (39.1%) were multidrug-resistant organisms. Twelve (54.5%) of 22 patients for whom empirical antimicrobial therapy was inappropriate were infected by a multidrug-resistant organism. Of 46 patients, 26 (56.5%) survived and 20 (43.5%) died. Exploring variables for association with in-hospital mortality identified > 75-year age (HR 2.97, 95% CI 1.15-7.68, p = 0.02), septic shock (HR 6.55, 95% CI 2.36-18.23, p < 0.001) and BSI onset ≤ 3 days (HR 4.68, 95% CI 1.40-15.63, p = 0.01) as risk factors independently associated with death. In our hospital, mortality among COVID-19 patients with BSI was high. While continued vigilance against these infections is essential, identification of risk factors for mortality may help to reduce fatal outcomes in patients with COVID-19.

Entities:  

Keywords:  COVID-19; antimicrobial resistance; bloodstream infection; mortality; risk factors; septic shock

Year:  2021        PMID: 33920701     DOI: 10.3390/jcm10081752

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  3 in total

1.  Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections.

Authors:  Michael A Pfaller; Cecilia G Carvalhaes; Sean DeVries; Paul R Rhomberg; Mariana Castanheira
Journal:  Med Mycol       Date:  2022-05-06       Impact factor: 3.747

2.  Impact of PBP4 Alterations on β-Lactam Resistance and Ceftobiprole Non-Susceptibility Among Enterococcus faecalis Clinical Isolates.

Authors:  Lorenzo M Lazzaro; Marta Cassisi; Stefania Stefani; Floriana Campanile
Journal:  Front Cell Infect Microbiol       Date:  2022-01-20       Impact factor: 5.293

3.  Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021).

Authors:  Ruwandi M Kariyawasam; Danielle A Julien; Dana C Jelinski; Samantha L Larose; Elissa Rennert-May; John M Conly; Tanis C Dingle; Justin Z Chen; Gregory J Tyrrell; Paul E Ronksley; Herman W Barkema
Journal:  Antimicrob Resist Infect Control       Date:  2022-03-07       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.